Amazon One Medical Has a National GLP-1 Program and Same-Day Delivery. DPC Practices Have Something Different.

Amazon One Medical launched a national GLP-1 management program on April 21. Cash-paying patients can access oral GLP-1 medications starting at $149 per month and injectable medications — Wegovy, Zepbound — starting at $299 per month. Patients with insurance can access the program for as little as $25 per month. Same-day delivery is available in roughly 3,000 cities, with plans to expand to 4,500 by year’s end.

Twelve days ago, the Medicare GLP-1 Bridge went live. Medicare Part D beneficiaries with obesity and qualifying conditions can now get Wegovy, Zepbound, or Foundayo at a flat $50 per month.

GLP-1 management has quietly become contested territory in primary care. Both developments are worth examining closely — because they sit on very different ground than what DPC practices offer, and understanding the distinction matters for how independent primary care physicians position themselves heading into the rest of 2026.

What Amazon One Medical Built

The GLP-1 Management Program integrates Amazon Pharmacy, One Medical providers, and telehealth into a single product. Patients start with pre-visit screening, move into a structured consultation, and then enter a protocol of regular follow-up visits with standardized monitoring and evidence-based treatment algorithms. Telehealth prescription renewals for existing GLP-1 users are available 24/7 for $29 per message.

Amazon’s footprint in primary care now spans One Medical’s clinic network, Prime membership benefits, and Health AI — an AI-assisted triage layer that launched across Amazon.com and the Amazon app in March, reaching 200 million Prime members. The GLP-1 program extends that infrastructure into one of the highest-growth areas in medicine. Healthcare Dive reported that the program explicitly pairs GLP-1 management with Amazon’s pharmacy and delivery logistics — a combination that no independent primary care practice can replicate at scale.

This is not a convenience play masquerading as care. Amazon brought real clinical structure to the program: physician oversight, safety protocols, follow-up monitoring, and integration into a patient’s broader primary care relationship at One Medical.

What the Medicare Bridge Changes

The Bridge changes the economics for a large and specific patient population. DPC physicians can write prescriptions under it without Medicare enrollment — a point worth emphasizing for practices that opted out of Medicare billing and may have assumed they couldn’t participate. Prior authorization is required, which adds a step. But for DPC practices already carrying Medicare-eligible patients with obesity and qualifying conditions, the Bridge means those patients can now access GLP-1 medications at a price that makes long-term use realistic.

The practical implication: DPC patients who have been avoiding GLP-1 therapy because of cost now have a path. And practices that haven’t thought through their GLP-1 clinical protocol are going to feel that change in their patient conversations.

The Structural Difference DPC Practices Have

Amazon’s program is built for scale. Evidence-based algorithms, standardized protocols, and embedded pharmacy logistics are how you manage GLP-1 patients across a national network without care quality becoming inconsistent. That’s not a limitation — it’s an engineering reality. At Amazon’s scale, standardization is what keeps care safe and functional.

DPC practices are built differently. A DPC physician carrying a panel of around 500 patients has the time and the ongoing relationship to manage GLP-1 therapy in ways that don’t reduce easily to a protocol. This matters specifically for GLP-1 patients because the therapy requires sustained, individualized management over months and years.

IAPAM’s May 2026 clinical guidance on GLP-1 management lays out what that management actually involves: dose titration over months to find the effective level, metabolic monitoring at appropriate intervals — A1C, lipid panels, blood pressure — active management of side effects including nausea and GI symptoms, screening for contraindications including thyroid history and pancreatitis risk, and integration with nutritional and behavioral support. These are not checkbox items. They are clinical decisions that benefit from knowing the patient.

A physician who has seen the same patient for three years knows their GI history, knows how they responded to previous medication adjustments, and can tell the difference between nausea from a dose increase and nausea from something else entirely. That clinical context doesn’t live in an algorithm. It lives in a relationship.

The Honest Comparison

Amazon’s model doesn’t fall short because it’s careless. It serves a specific patient profile well: someone who you might describe as a straightforward GLP-1 candidate — no significant comorbidities, clear indication, standard dosing, willing to follow a protocol. For that patient, Amazon’s program is real medicine delivered with convenience and transparent pricing. It’s worth taking seriously.

The DPC patient population tends to include people who have made a deliberate choice about their relationship with their physician. People who want to see the same doctor, who want longer appointments, who want to be known as a patient rather than processed as a case. For that population, GLP-1 management in a DPC practice isn’t just a different product. It’s the product they’re already paying for.

What This Means

Amazon’s entry into GLP-1 management is a signal about market size. A company with 200 million Prime members and a national pharmacy network does not build specialized clinical programs for niche conditions. GLP-1 management is now a mainstream primary care service that can be standardized, priced transparently, and delivered at scale. Amazon is treating it that way.

DPC practices that have not yet developed a clear GLP-1 clinical protocol are competing in that landscape without a defined position. The practices that are building out their approach — tracking metabolic markers systematically, investing time in the titration conversation, treating GLP-1 therapy as a multi-year clinical relationship — are doing something Amazon’s standardized program does not deliver at the patient level.

The Medicare Bridge made GLP-1 medications accessible to millions more people. Amazon made GLP-1 management a national consumer product. DPC has a structural home for the patients for whom neither of those options is the right fit — the people for whom the depth of the relationship is the point. That is a real and defensible position. The question is whether individual practices understand it clearly enough to make it visible.